Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tacrolimus in Combination With Anti-CD20 Monoclonal Antibody (Ripertamab) in the Initial Treatment of Patients With Minimal Change Disease: a Multi-center Randomized Controlled Clinical Trial

NCT06405100 is registered in ClinicalTrials.gov with Air Force Military Medical University, China as lead sponsor.

NCT NCT06405100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06405100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tacrolimus in Combination With Anti-CD20 Monoclonal Antibody (Ripertamab) in the Initial Treatment of Patients With Minimal Change Disease: a Multi-center Randomized Controlled Clinical Trial
Lead sponsor
Air Force Military Medical University, China
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 31, 2024
Completion date
April 30, 2027
Enrollment
81 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

minimal change disease